Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (469)	7/9/2003 7:36:41 PM
From: SemiBull	Read Replies (1) \| Respond to of 668

Curis Appoints Dr. Joseph M. Davie to Board of Directors Wednesday July 9, 8:36 am ET Former Senior Biogen Executive Adds Expertise as Curis Increases Its Product Development Focus CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 9, 2003--Curis, Inc. (NASDAQ:CRIS - News) today announced the appointment of Joseph M. Davie, Ph.D., M.D. to its Board of Directors. Most recently, Dr. Davie was the Senior Vice President of Research at Biogen during the period that Biogen developed and received approval for its first major product, Avonex. It is expected that he will provide valuable perspective to Curis as it evolves towards a more focused emphasis on product development. Prior to Biogen, Dr. Davie held several senior positions at the pharmaceutical company, G.D. Searle and Co., including Senior Vice President of Science and Technology and President of Research and Development. He has also held numerous academic positions at the Washington University School of Medicine in St. Louis, Missouri, including Professor and Head of the Department of Microbiology and Immunology. Dr. Davie received his Ph.D. from Indiana University and his M.D. from the Washington University School of Medicine. "I am delighted to join with Curis," said Dr. Davie. "Curis' signaling pathways technology platform has proved to be a very rich source of new and novel drug candidates, and I look forward to contributing to the company in their therapeutic development efforts." Daniel Passeri, Curis' President and Chief Executive Officer, commented, "We are very pleased to have Dr. Davie join Curis' Board of Directors. Dr. Davie brings the kind of balanced expertise that will be especially useful during this period of transition, as Curis continues to evolve its product development capabilities while maintaining its high standards for research excellence." About Curis, Inc. Curis, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. Curis' product development involves the use of proteins or small molecules to modulate these pathways. Curis has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the Curis web site at www.curis.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release. Contact: For Curis, Inc. Christopher U. Missling, Ph.D., 617/503-6587 or Marc F. Charette, Ph.D., 617/503-6629 Source: Curis, Inc.